PRCT Stock Recent News

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript

SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

With the innovation sector moving at full speed, it's time for investors to consider the best tech stocks to buy now but not necessarily for the reason you might assume. Yes, the exchange-traded fund Technology Select Sector SPDR Fund (NYSEARCA: XLK ) has easily outperformed the benchmark SPDR S&P 500 ETF Trust (NYSEARCA: SPY ) over the past five years, 159% to 68%.

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2023 Wells Fargo Healthcare Conference in Boston. Management is scheduled to present on Thursday, September 7 at 3:00 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, and growth from its installed base, with a record number of systems placed in Q2. Net-net, reiterate buy, eyeing a $40 price objective.